Lilly is gearing up to file Cyramza for first-line treatment of certain lung cancer patients, after new trial data showed that the drug significantly extended progression-free survival (PFS) in this setting.
Read More
Eli Lilly and Sigilon Therapeutics have announced a global collaboration to develop encapsulated cell therapies for type I diabetes.
Read More
Eli Lilly’s Cyramza has hit its primary goal in a late-stage study showing extended progression-free survival in patients with gastric cancer, but the drug failed to improve overall survival, a secondary endpoint.
Read More
